Nouscom
Nouscom is developing Nous-209, an off-the-shelf viral-vector vaccine encoding 209 shared frameshift neoantigens to intercept cancer in Lynch syndrome carriers.
Phase 1b/2 in Lynch carriers (Nature Medicine, March 2026) showed safety and immune responses in most participants; re-treatment and long-term follow-up data selected for an ESMO 2026 oral. Also tested with pembrolizumab in MSI-high tumours.
Pages like this
not linked directly; found by shared links- Key paperFirst trial of a vaccine against the shared neoantigens of mismatch-repair-deficient cancers
Shares A randomised trial of a shared-antigen vaccine to prevent Lynch syndrome cancers, Off-the-shelf cancer vaccines, Neoantigen, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
- IdeaCancer interception vaccines for high-risk carriers
Shares A randomised trial of a shared-antigen vaccine to prevent Lynch syndrome cancers, Off-the-shelf cancer vaccines, Chemoprevention & risk-reducing surgery, Colorectal cancer.
- IdeaA frameshift neoantigen vaccine for Lynch syndrome carriers as the first preventive cancer vaccine approval
Shares Off-the-shelf cancer vaccines, Neoantigen, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Colorectal cancer.
- IdeaGet every Lynch syndrome carrier onto the right dose of aspirin
Shares Chemoprevention & risk-reducing surgery, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Colorectal cancer.
- PersonNina Bhardwaj
Shares Off-the-shelf cancer vaccines, Neoantigen.
- PersonVincent K. Tuohy
Shares Off-the-shelf cancer vaccines, Chemoprevention & risk-reducing surgery.
- CompanyGritstone bio
- TechnologyCancer interception vaccines
Shares Off-the-shelf cancer vaccines, Chemoprevention & risk-reducing surgery, Colorectal cancer.